Perampanel as adjunctive therapy in drug resistant epilepsy in adolescents and children waiting for epilepsy surgery: a multicenter observational study in Thailand

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20220322006

Enrollment

Registered

2022-03-22

Start date

2020-10-29

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The patients with the age between 1 month and 18 years treated with PER and diagnosed with DRE and in the waiting list for epilepsy surgery Perampanel anti-seizure medication drug-resistant treatment-resistant epilepsy

Interventions

The children with drug resistant epilepsy who received perampanel.

Treatment

Children with epilepsy

Eligibility

Sex/Gender

All

Age

1 Months to 18 Years

Inclusion criteria

Inclusion criteria: 1. patients with the age between 1 month and 18 years treated with PER, 2. having complete records of baseline seizure frequency for at least 3 months prior to starting PER, 3. taking PER for at least 6 months, 4. diagnosed with DRE and in the waiting list for epilepsy surgery.

Exclusion criteria

Exclusion criteria: 1. patients with generalized epilepsy, 2. patients with epilepsy syndrome.

Design outcomes

Primary

Measure	Time frame
seizure reduction 180 days extract from the medical record	—

Secondary

Measure	Time frame
adverse effect, ataxia, mood disturbamce 180 days extract from the medical record	—

Countries

Thailand

Contacts

Public ContactPiradee Suwanpakdee

Phramongkutklao Hospital

piradee@pedpmk.org0814383634

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026